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Abstract
Purpose Treatment of metastatic germ cell cancer (GCC) is based on the International Germ Cell Cancer Collaborative 
Group (IGCCCG) prognostic classification published in 1997. 5-year survival rates were reported to be 91%, 79%, and 48% 
for patients with good, intermediate and poor prognosis, respectively. However, treatment results may have improved over 
time due to cumulative experience, improved supportive care and modern-type chemotherapy.
Methods Patients with metastatic GCC who received cisplatin-based chemotherapy at two institutions in Munich between 
2000 and 2013 were retrospectively studied. Clinical characteristics, treatment and outcomes were analyzed with respect to 
the IGCCG prognostic classification.
Results Of 225 patients (median age 35 years), 72 (32%) had seminoma (S) and 153 (68%) nonseminoma. 175 (78%), 30 
(13%) and 20 patients (9%) had good, intermediate and poor prognosis according to the IGCCCG classification. The 2-year-
progression free survival of patients with good, intermediate and poor prognosis was 91%, 83% and 37%, and the 5-year-
overall survival (OS) was 98%, 96%, and 66%, respectively. There was no significant difference in the OS between patients 
in the good and intermediate prognosis group.
Conclusion Compared to data from the original IGCCCG classification system, the outcome of patients with metastatic 
GCC has considerably improved over time. While the prognosis of intermediate-risk patients is excellent, treatment in the 
poor-prognosis group remains to be improved.
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Introduction
Testicular germ cell cancer is the most common cancer in 
men aged 18–40 years with an estimated 4120 new cases 
detected in Germany in 2016 (Robert-Koch-Institute 2019). 
Today, a cure is expected in 95% of all patients diagnosed 
with testicular cancer and in approximately 80% of patients 
with metastatic disease (Hanna and Einhorn 2014). Treat-
ment of metastatic germ cell cancer (GCC) is based on the 
1997 International Germ Cell Cancer Collaborative Group 
(IGCCCG) prognostic classification (IGCCCG 1997; Beyer 
et al. 2013; Albers et al. 2015; Honecker et al. 2018). Three 
cycles of cisplatin, etoposide, bleomycin (BEP) combina-
tion chemotherapy have become standard of care for good-
risk patients while four cycles of BEP are the reference for 
intermediate- and poor-risk patients (Beyer et al. 2013; 
Honecker et al. 2018). According to the IGCCCG cohort, 
five-year survival rates are 91%, 79%, and 48% for patients 
with good, intermediate and poor prognosis, respectively 
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(IGCCCG 1997). However, the IGCCCG classification is 
based on treatments applied between 1975 and 1990. Recent 
data indicate that the outcome of patients with metastatic 
GCC may have improved over time due to cumulative expe-
rience of treating physicians, improved supportive care and 
modern-type chemotherapy (van Dijk et al. 2006; Raggi 
et al. 2015). The aim of the present study was to analyze the 
outcome of patients with metastatic GCC treated between 
2000 and 2013 at two experienced institutions in Munich, 
Germany. We presumed that the outcome of metastatic GCC 
has considerably improved compared to the original IGC-
CCG experience.
Methods
All patients who underwent first line chemotherapy between 
January 2000 and December 2013 at Private Practice 
of Oncology and at the Department of Hematology and 
Oncology, Harlaching Hospital, both located in Munich, 
were identified through the institutional database. Inclu-
sion criteria were (1) pathology proven metastatic GCC, (2) 
age ≥ 17 years, (3) start of chemotherapy for metastatic GCC 
between January 2000 and December 2013, and (4) at least 
2-years follow-up. Patients were excluded if data on tumor 
stage, treatment or follow-up were incomplete.
The medical records were reviewed with regard to age at 
time of initial diagnosis, histopathology, stage, tumor marker 
levels, metastatic spread, type and duration of chemotherapy, 
and outcome.
The primary endpoint was the 5-years overall survival 
(OS) rate. Secondary endpoints included progression-free 
survival (PFS) as well as PFS and OS of relapsed patients. 
The study was approved by the Ethics committee of Ludwig-
Maximilians-University Munich. The study was performed 
in accordance with the Declaration of Helsinki.
Statistics
PFS was measured from the beginning of the chemother-
apy to the time of progression, relapse or death. OS was 
calculated from the beginning of the chemotherapy to last 
follow-up or to death from any cause. Patients without an 
event were censored at the date of last follow-up. The prob-
ability of PFS and OS was determined by the Kaplan–Meier 
Method and differences between subgroups of patients were 
assessed by the log-rank test. Statistical analyses includ-
ing descriptive statistics such as frequency, mean, median, 
range, inter-quartile range, minimum and maximum were 
performed by using SPSS software (IBM SPSS Statistic, 
version 21.0). All p-values were two-sided. P values of 0.05 
or less were considered statistically significant.
Results
Patient characteristics
Of 255 patients identified, 30 were excluded due to incom-
plete data. Main characteristics of the 225 patients included 
into the study are outlined in Table 1. The median age of the 
cohort was 35 years (range 17–66). Seminoma and nonsemi-
noma were diagnosed in 72 (32%) and 153 (68%) patients, 
and 204 patients (91%) had a primary gonadal GCC. The 
cohort includes 56 patients managed with active surveil-
lance for stage I disease who developed metastases after a 
median time of 9.5 months (range 0.5–15). According to the 
IGCCCG classification system, 175 (78%), 30 (13%) and 
20 patients (9%) had good, intermediate and poor prognosis 
GCC as compared to 60%, 26% and 14% in the original 
IGCCCG cohort.
Table 1  Patients characteristics and first line treatment
a Spleen, Intestine, Kidney
Patients (n) 225


















Relapse from Stage I 56 (25%)
Median time to progression 9.5 month 
(range 
0.5–15)
IGCCCG risk at relapse from Stage I
  Good 52
  Intermediate 4
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Type of first line chemotherapy and the number of cycles 
given are shown in Table 2. The vast majority of patients 
received three to four cycles of platinum-based chemo-
therapy, while primary high-dose chemotherapy (HDCT) 
was applied to three patients in the poor prognosis group. 
All nonseminoma patients with residual tumor > 1 cm after 
chemotherapy were routinely scheduled for secondary sur-
gery. Thus, 33 of 225 (15%) patients underwent secondary 
retroperitoneal lymph node dissection (n = 28), and/or sec-
ondary surgery of the lungs (n = 5), liver (n = 1), mediastinal 
(n = 3) and infraclavicular lymph nodes (n = 1). Histopatho-
logical examination revealed necrosis/fibrosis in 16 of 38 
(42%) resection specimens, teratoma in 10 (26%), vital GCC 
in 7 (18%), and malignancies other than GCC in 5 (13%) 
(spindle cell tumor [n = 3], undifferentiated non-small cell 
carcinoma [n = 1], not specified [n = 1]).
Salvage treatment in relapsed patients was applied to 14, 
5 and 11 patients of the good, intermediate and poor progno-
sis group, respectively. It consisted of surgery alone for tera-
toma in seven of 30 (23%) patients, all but one of whom are 
alive in ongoing remission. Conventional dose first salvage 
chemotherapy (CDCT) and HDCT were applied to 16 and 7 
patients, respectively. CDCT regimens used were cisplatin, 
etoposide, ifosfamide (VIP, n = 13), cisplatin, ifosfamide, 
paclitaxel (TIP, n = 1), and gemcitabine, oxaliplatin, pacli-
taxel (GOP, n = 2). Second and higher relapses occurred in 
twelve of 30 patients (40%). Second salvage chemotherapy 
consisted of GOP (n = 2), gemcitabine, paclitaxel (n = 2), 
cisplatin, epirubicine (n = 1), oxaliplatin, paclitaxel (n = 1), 
oxaliplatin, irinotecan (n = 1), and HDCT (n = 5). Of the 12 
patients undergoing second salvage chemotherapy, 6 died of 
GCC while the others are alive and well. Palliative treatment 
with everolimus was given to two patients within a clinical 
trial (Fenner et al. 2019).
Survival
After a median follow-up of 95 months (95% confidence 
interval [CI], 88–104), the 2-year-PFS of patients with good, 
intermediate and poor prognosis was 91% (95% CI 87–96), 
83% (95% CI 70–98) and 37% (95% CI 20–66) (Fig. 1). The 
corresponding 5-year-PFS of the original IGCCCG cohort 
has been reported to be 88%, 78% and 41%. In our analysis 
the difference between the good and poor prognosis group 
(P < 0.0001) and between the intermediate and poor prog-
nosis group (P = 0.00045) was statistically significant. By 
contrast, the difference between the good and intermediate 
group was not statistically significant (P = 0.281).
Overall, eleven of 225 (5%) patients have died, ten of 
which from GCC and one from community-acquired pneu-
monia unrelated to cancer treatment (Table 3). The 5-year-
OS of our cohort was 98% (95% CI 95–100), 96% (95% CI 
90–100), and 66% (95% CI 47–93), for the good, intermedi-
ate and poor prognosis group, respectively (Fig. 2; Table 3). 
This compares favorably to the 5-year-OS of 91%, 79% and 
48% predicted by the original IGCCCG score. The corre-
sponding mean survival times of our cohort were 152 (95% 
CI 148–155), 147 (95% CI 139–156), and 100 months (95% 
CI 72–128). There was no significant difference in the OS 
between patients in the good and intermediate prognosis 
group (P = 0.754). By contrast, the OS of patients from the 
good and the intermediate prognosis group was significantly 
superior to that of the poor prognosis group (P < 0.0001 and 
P = 0.004, respectively). Further, the 5-year-OS was signifi-
cantly better in poor-risk patients without non-pulmonary 
Table 2  First line treatment for metastatic GCC 
a Including PEB—> VIP (n = 3)
b PE × 3 (n = 3), PEB × 2 (n = 1)
Good prognosis (n = 175)
 3 × PEBa 159 (91%)
 4 × PEB 9 (5%)
 4 × PE 3 (2%)
 Otherb 4 (2%)
Intermediate prognosis (n = 30)
 4 × PEB 25 (83%)
 2 × PEB— > 2 × VIP 1 (3%)
 3 × PEB 4 (13%)
Poor prognosis (n = 20)
 4 × PEB 13 (65%)
 1 × VIP—> 3 × PEB 4 (20%)
 VIP + HDCT 3 (15%)
Fig. 1  Progression-free survival according to IGCCCG prognostic 
groups
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visceral metastasis (NPVM) compared to patients with 
NPVM (5-year-OS 100% vs. 38%, P = 0.033).
The cumulative 5-year-OS of relapsed patients was 75% 
(95% CI 60–93) without significant differences between 
the good, intermediate and poor prognosis group (Fig. 3) 
(P = 0.238). Of 21 patients treated with first salvage cis-
platin-based CDCT (n = 14) or carboplatin-based HDCT 
(n = 7) the International Prognostic Factors Study Group 
(IPFSG) scores were very low (n = 2), low (n = 3), interme-
diate (n = 5), high (n = 6), and very high (n = 5), respectively 
(International Prognostic Factors Study Group et al. 2010). 
However, differences in survival between groups were not 
calculated due to low number of patients in each group.
Discussion
There are two major findings from our study. First, the 
5-year-OS of patients with metastatic GCC has markedly 
improved compared to data from the 1997 IGCCCG clas-
sification system. The 5-year OS probabilities were 98% 
vs. 91%, 96% vs. 79%, and 66% vs. 48% for patients in the 
good-, intermediate- and poor-risk group, respectively. 
As we did not observe similar improvements in the PFS, 
the efficacy of first-line chemotherapy in metastatic GCC 
appears to be unchanged over the last decades. Indeed, 
while the substitution of etoposide for vinblastine as well 
as cumulative experience translated into improved survival 
rates in the early nineties (Williams et al. 1987; Gerl et al. 
1996), a number of randomized controlled-trials on first-line 
chemotherapy published in the last two decades failed to 
demonstrate significant improvements in survival over stand-
ard BEP (Nichols et al. 1998; Motzer et al. 2007; Daugaard 
et al. 2011; de Wit et al. 2012; Fizazi et al. 2014; Necchi 
et al. 2015). By contrast, the improvement in the 5-years 
OS is likely due to salvage therapies that were given more 
consequently to a higher proportion of patients with relapsed 
GCC than this may have been the case some decades ago. 
In fact, standard first salvage regimens such as VIP, TIP or 
HDCT were applied as first salvage to the vast majority of 
relapsed patients if they did not undergo curative surgery for 
Table 3  Outcome according to the IGCCCG risk classification
2-years PFS
 Good 91% (95% CI 87–96)
 Intermediate 83% (95% CI 70–98)
 Poor 37% (95% CI 20–66)
5-years OS
 Good 98% (95% CI 95–100)
 Intermediate 96% (95% CI 90–100)






 Good (n) 4/175 (2%)
 Intermediate (n) 1/30 (3%)
 Poor (n) 6/20 (30%)
Fig. 2  Overall survival according to IGCCCG prognostic groups
Fig. 3  Overall survival in relapsed vs. non-relapsed patients
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teratoma only (Kondagunta et al. 2005; Lorch et al. 2012; 
Adra et al. 2017). Further, adherence to structured follow-up 
schedules may have contributed to earlier diagnosis of GCC 
relapses (Albers et al. 2015; Cathomas et al. 2011).
Second, we observed no significant difference in the OS 
between good-risk and intermediate-risk patients. Thus, 
the IGCCCG prognostic score no longer predicts differ-
ent survival probabilities for the groups of good and inter-
mediate-risk patients. Similar data were recently reported 
from a Swiss cohort that included 204 patients treated from 
1991 to 2016 (Fankhauser et al. 2018). As in our study, no 
significant difference in overall survival between good and 
intermediate risk patients was found. Another large retro-
spective observational study on 707 intermediate prognosis 
GCC patients reported a 5-year-OS rate of 89% in patients 
treated from 1997 to 2016, which was significantly superior 
to the 83% 5-years OS rate of 237 patients treated from 1979 
to 1996 (Seidel et al. 2018). Of note, a lactate dehydrogenase 
(LDH) level > 2 upper limit of normal (UNL) and AFP levels 
of > 6200 IU/ml were independently associated with inferior 
survival in this study. Further, first-line treatment with three 
cycles of BEP was given to 53 (7%) patients with no sig-
nificant differences found in OS and PFS between patients 
treated with three and four cycles of BEP. However, patient 
numbers were too low to draw any firm conclusion on 
whether de-intensification of treatment may be an option. In 
a subsequent analysis of the cohort intermediate risk patients 
with AFP values > 6000 IU/ml and LDH > 3 UNL revealed 
an outcome similar to the poor prognosis category (Seidel 
et al. 2019). Moreover, patients with AFP levels > 1982 IU/
ml had a higher risk of disease recurrence (recurrence rate 
20% vs. 31%; P = 0.02) as did patients with LDH levels > 2 
UNL (recurrence rate 29% vs. 42.5%; P = 0.047). Thus, 
based on these findings and given the lack of data from pro-
spective randomized trials, three cycles of BEP may only be 
used on an individual basis in intermediate risk patients with 
LDH level ≤ 2 UNL and AFP levels ≤ 1982 IU/ml (Seidel 
et al. 2018, 2019). A randomized controlled trial comparing 
three with four cycles of BEP in intermediate risk patients 
without high-risk features is warranted.
Our findings compare favorably with recent results from an 
analysis of a large data set collected to redefine the IGCCCG 
classification (Gillessen et al. 2019; Beyer et al. 2020). An 
international consortium contributed data on 9530 advanced 
non-seminoma GCC patients treated with cisplatin/etoposide 
based first line chemotherapy between 1990 and 2013. The 
5-years OS was 96%, 89% and 67% for patients in the good-, 
intermediate- and poor-risk group, respectively (Gillessen 
et al. 2019). Further, based on data from 2302 advanced semi-
noma patients, 5-years OS rates were reported to be 95% and 
87% for good- and intermediate-risk patients, respectively 
(Beyer et al. 2020). It should be noted that our data were also 
included in the IGCCCG project.
The 66% 5-years OS rate of poor-risk patients remains 
unsatisfactory although this represents an improvement com-
pared to the original IGCCCG risk classification. However, 
attempts to improve overall survival by intensification of first 
line chemotherapy have failed (Motzer et al. 2007; Daugaard 
et al. 2011; Necchi et al. 2015), although a significant PFS-
advantage was achieved by use of an intensified chemotherapy 
schedule for patients with inappropriate tumor marker decline 
(Fizazi et al. 2014).
Limitations of the present study are its retrospective design 
and the relatively small sample size. However, our analysis 
provides important real-life data on clinical outcomes of 
patients with metastatic GCC mostly managed outside a clini-
cal trial setting.
In conclusion, compared to data from the original IGCCCG 
classification system, the outcome of patients with metastatic 
GCC has markedly improved. While the prognosis of interme-
diate-risk patients is excellent, treatment in the poor-prognosis 
group remains to be improved.
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